Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 216

1.

Nuclear Circulating Tumor Cell Androgen Receptor Variant 7 in Castration-Resistant Prostate Cancer: The Devil Is in the Detail.

Plymate SR, Sharp A, de Bono JS.

JAMA Oncol. 2018 Jun 28. doi: 10.1001/jamaoncol.2018.1615. [Epub ahead of print] No abstract available.

PMID:
29955776
2.

A phase I study of niclosamide in combination with enzalutamide in men with castration-resistant prostate cancer.

Schweizer MT, Haugk K, McKiernan JS, Gulati R, Cheng HH, Maes JL, Dumpit RF, Nelson PS, Montgomery B, McCune JS, Plymate SR, Yu EY.

PLoS One. 2018 Jun 1;13(6):e0198389. doi: 10.1371/journal.pone.0198389. eCollection 2018.

3.

Intense Exercise for Survival among Men with Metastatic Castrate-Resistant Prostate Cancer (INTERVAL-GAP4): a multicentre, randomised, controlled phase III study protocol.

Newton RU, Kenfield SA, Hart NH, Chan JM, Courneya KS, Catto J, Finn SP, Greenwood R, Hughes DC, Mucci L, Plymate SR, Praet SFE, Guinan EM, Van Blarigan EL, Casey O, Buzza M, Gledhill S, Zhang L, Galvão DA, Ryan CJ, Saad F.

BMJ Open. 2018 May 14;8(5):e022899. doi: 10.1136/bmjopen-2018-022899.

4.

Targeting Bromodomain and Extra-Terminal (BET) Family Proteins in Castration-Resistant Prostate Cancer (CRPC).

Welti J, Sharp A, Yuan W, Dolling D, Nava Rodrigues D, Figueiredo I, Gil V, Neeb A, Clarke M, Seed G, Crespo M, Sumanasuriya S, Ning J, Knight E, Francis JC, Hughes A, Halsey WS, Paschalis A, Mani RS, Raj GV, Plymate SR, Carreira S, Boysen G, Chinnaiyan AM, Swain A, de Bono JS; International SU2C/PCF Prostate Cancer Dream Team.

Clin Cancer Res. 2018 Jul 1;24(13):3149-3162. doi: 10.1158/1078-0432.CCR-17-3571. Epub 2018 Mar 19.

PMID:
29555663
5.

The potential of AR-V7 as a therapeutic target.

Uo T, Plymate SR, Sprenger CC.

Expert Opin Ther Targets. 2018 Mar;22(3):201-216. doi: 10.1080/14728222.2018.1439016. Epub 2018 Feb 15.

PMID:
29417861
6.

Small-Molecule Activators of Protein Phosphatase 2A for the Treatment of Castration-Resistant Prostate Cancer.

McClinch K, Avelar RA, Callejas D, Izadmehr S, Wiredja D, Perl A, Sangodkar J, Kastrinsky DB, Schlatzer D, Cooper M, Kiselar J, Stachnik A, Yao S, Hoon D, McQuaid D, Zaware N, Gong Y, Brautigan DL, Plymate SR, Sprenger CCT, Oh WK, Levine AC, Kirschenbaum A, Sfakianos JP, Sears R, DiFeo A, Ioannou Y, Ohlmeyer M, Narla G, Galsky MD.

Cancer Res. 2018 Apr 15;78(8):2065-2080. doi: 10.1158/0008-5472.CAN-17-0123. Epub 2018 Jan 22.

PMID:
29358171
7.

Role of Androgen Receptor Variants in Prostate Cancer: Report from the 2017 Mission Androgen Receptor Variants Meeting.

Luo J, Attard G, Balk SP, Bevan C, Burnstein K, Cato L, Cherkasov A, De Bono JS, Dong Y, Gao AC, Gleave M, Heemers H, Kanayama M, Kittler R, Lang JM, Lee RJ, Logothetis CJ, Matusik R, Plymate S, Sawyers CL, Selth LA, Soule H, Tilley W, Weigel NL, Zoubeidi A, Dehm SM, Raj GV.

Eur Urol. 2018 May;73(5):715-723. doi: 10.1016/j.eururo.2017.11.038. Epub 2017 Dec 16.

PMID:
29258679
8.

Supraphysiologic Testosterone Therapy in the Treatment of Prostate Cancer: Models, Mechanisms and Questions.

Mohammad OS, Nyquist MD, Schweizer MT, Balk SP, Corey E, Plymate S, Nelson PS, Mostaghel EA.

Cancers (Basel). 2017 Dec 6;9(12). pii: E166. doi: 10.3390/cancers9120166. Review.

9.

Novel Junction-specific and Quantifiable In Situ Detection of AR-V7 and its Clinical Correlates in Metastatic Castration-resistant Prostate Cancer.

Zhu Y, Sharp A, Anderson CM, Silberstein JL, Taylor M, Lu C, Zhao P, De Marzo AM, Antonarakis ES, Wang M, Wu X, Luo Y, Su N, Nava Rodrigues D, Figueiredo I, Welti J, Park E, Ma XJ, Coleman I, Morrissey C, Plymate SR, Nelson PS, de Bono JS, Luo J.

Eur Urol. 2018 May;73(5):727-735. doi: 10.1016/j.eururo.2017.08.009. Epub 2017 Sep 1.

PMID:
28866255
10.

Allosteric alterations in the androgen receptor and activity in prostate cancer.

Uo T, Plymate SR, Sprenger CC.

Endocr Relat Cancer. 2017 Sep;24(9):R335-R348. doi: 10.1530/ERC-17-0108. Review.

11.

Novel Androgen Receptor Coregulator GRHL2 Exerts Both Oncogenic and Antimetastatic Functions in Prostate Cancer.

Paltoglou S, Das R, Townley SL, Hickey TE, Tarulli GA, Coutinho I, Fernandes R, Hanson AR, Denis I, Carroll JS, Dehm SM, Raj GV, Plymate SR, Tilley WD, Selth LA.

Cancer Res. 2017 Jul 1;77(13):3417-3430. doi: 10.1158/0008-5472.CAN-16-1616. Epub 2017 May 4.

12.

Neoadjuvant Enzalutamide Prior to Prostatectomy.

Montgomery B, Tretiakova MS, Joshua AM, Gleave ME, Fleshner N, Bubley GJ, Mostaghel EA, Chi KN, Lin DW, Sanda M, Novotny W, Wu K, Kantoff PW, Marck BT, Plymate S, Balk SP, Nelson PS, Matsumoto AM, Lis RT, Kibel A, Haas GP, Krivoshik A, Hannah A, Taplin ME.

Clin Cancer Res. 2017 May 1;23(9):2169-2176. doi: 10.1158/1078-0432.CCR-16-1357. Epub 2016 Nov 9.

13.

Truncation and constitutive activation of the androgen receptor by diverse genomic rearrangements in prostate cancer.

Henzler C, Li Y, Yang R, McBride T, Ho Y, Sprenger C, Liu G, Coleman I, Lakely B, Li R, Ma S, Landman SR, Kumar V, Hwang TH, Raj GV, Higano CS, Morrissey C, Nelson PS, Plymate SR, Dehm SM.

Nat Commun. 2016 Nov 29;7:13668. doi: 10.1038/ncomms13668.

14.

Systematic and functional characterization of novel androgen receptor variants arising from alternative splicing in the ligand-binding domain.

Uo T, Dvinge H, Sprenger CC, Bradley RK, Nelson PS, Plymate SR.

Oncogene. 2017 Mar;36(10):1440-1450. doi: 10.1038/onc.2016.313. Epub 2016 Oct 3.

15.

Response: letter to the editor.

Schweizer MT, Plymate SR.

Expert Opin Ther Targets. 2017 Feb;21(2):229. doi: 10.1080/14728222.2016.1214400. Epub 2016 Aug 17. No abstract available.

PMID:
27494249
16.

AR-V7 Protein in Circulating Tumor Cells-The Decider for Therapy?

Montgomery RB, Plymate SR.

JAMA Oncol. 2016 Nov 1;2(11):1450-1451. doi: 10.1001/jamaoncol.2016.2360. No abstract available.

PMID:
27261766
17.

Second-Generation HSP90 Inhibitor Onalespib Blocks mRNA Splicing of Androgen Receptor Variant 7 in Prostate Cancer Cells.

Ferraldeschi R, Welti J, Powers MV, Yuan W, Smyth T, Seed G, Riisnaes R, Hedayat S, Wang H, Crespo M, Nava Rodrigues D, Figueiredo I, Miranda S, Carreira S, Lyons JF, Sharp S, Plymate SR, Attard G, Wallis N, Workman P, de Bono JS.

Cancer Res. 2016 May 1;76(9):2731-42. doi: 10.1158/0008-5472.CAN-15-2186.

18.

Targeting Androgen Receptor Activation Function-1 with EPI to Overcome Resistance Mechanisms in Castration-Resistant Prostate Cancer.

Yang YC, Banuelos CA, Mawji NR, Wang J, Kato M, Haile S, McEwan IJ, Plymate S, Sadar MD.

Clin Cancer Res. 2016 Sep 1;22(17):4466-77. doi: 10.1158/1078-0432.CCR-15-2901. Epub 2016 May 2.

19.

Analytical Validation and Clinical Qualification of a New Immunohistochemical Assay for Androgen Receptor Splice Variant-7 Protein Expression in Metastatic Castration-resistant Prostate Cancer.

Welti J, Rodrigues DN, Sharp A, Sun S, Lorente D, Riisnaes R, Figueiredo I, Zafeiriou Z, Rescigno P, de Bono JS, Plymate SR.

Eur Urol. 2016 Oct;70(4):599-608. doi: 10.1016/j.eururo.2016.03.049. Epub 2016 Apr 23.

20.

Targeting constitutively active androgen receptor splice variants in castration resistant prostate cancer.

Schweizer MT, Plymate SR.

Expert Opin Ther Targets. 2016 Aug;20(8):903-6. doi: 10.1517/14728222.2016.1159676. Epub 2016 Mar 21. No abstract available.

21.

Classical and Non-Classical Roles for Pre-Receptor Control of DHT Metabolism in Prostate Cancer Progression.

Zhang A, Zhang J, Plymate S, Mostaghel EA.

Horm Cancer. 2016 Apr;7(2):104-13. doi: 10.1007/s12672-016-0250-9. Epub 2016 Jan 21. Review.

22.

BET Bromodomain Inhibitors Enhance Efficacy and Disrupt Resistance to AR Antagonists in the Treatment of Prostate Cancer.

Asangani IA, Wilder-Romans K, Dommeti VL, Krishnamurthy PM, Apel IJ, Escara-Wilke J, Plymate SR, Navone NM, Wang S, Feng FY, Chinnaiyan AM.

Mol Cancer Res. 2016 Apr;14(4):324-31. doi: 10.1158/1541-7786.MCR-15-0472. Epub 2016 Jan 20.

23.

Expression of androgen receptor splice variants in clinical breast cancers.

Hickey TE, Irvine CM, Dvinge H, Tarulli GA, Hanson AR, Ryan NK, Pickering MA, Birrell SN, Hu DG, Mackenzie PI, Russell R, Caldas C, Raj GV, Dehm SM, Plymate SR, Bradley RK, Tilley WD, Selth LA.

Oncotarget. 2015 Dec 29;6(42):44728-44. doi: 10.18632/oncotarget.6296.

24.

Differential Effects of Meal Challenges on Cognition, Metabolism, and Biomarkers for Apolipoprotein E ɛ4 Carriers and Adults with Mild Cognitive Impairment.

Hanson AJ, Bayer JL, Baker LD, Cholerton B, VanFossen B, Trittschuh E, Rissman RA, Donohue MC, Moghadam SH, Plymate SR, Craft S.

J Alzheimers Dis. 2015;48(1):205-18. doi: 10.3233/JAD-150273.

PMID:
26401941
25.

UDP-glucuronosyltransferase Enzymes in Prostate Cancer Progression: Is Only Androgen Catabolism Involved?

Mostaghel EA, Zhang A, Plymate S.

Eur Urol. 2016 Apr;69(4):610-612. doi: 10.1016/j.eururo.2015.08.025. Epub 2015 Aug 28. No abstract available.

PMID:
26318705
26.

Metformin effects on biochemical recurrence and metabolic signaling in the prostate.

Winters B, Plymate S, Zeliadt SB, Holt S, Zhang X, Hu E, Lin DW, Morrissey C, Wooldridge B, Gore JL, Porter MP, Wright JL.

Prostate. 2015 Nov;75(15):1694-703. doi: 10.1002/pros.23049. Epub 2015 Jul 22.

27.

Androgen receptor splice variant V7 (AR-V7) in circulating tumor cells: a coming of age for AR splice variants?

Sprenger C, Uo T, Plymate S.

Ann Oncol. 2015 Sep;26(9):1805-7. doi: 10.1093/annonc/mdv311. Epub 2015 Jul 21. No abstract available.

28.

Integrative Clinical Genomics of Advanced Prostate Cancer.

Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, Montgomery B, Taplin ME, Pritchard CC, Attard G, Beltran H, Abida W, Bradley RK, Vinson J, Cao X, Vats P, Kunju LP, Hussain M, Feng FY, Tomlins SA, Cooney KA, Smith DC, Brennan C, Siddiqui J, Mehra R, Chen Y, Rathkopf DE, Morris MJ, Solomon SB, Durack JC, Reuter VE, Gopalan A, Gao J, Loda M, Lis RT, Bowden M, Balk SP, Gaviola G, Sougnez C, Gupta M, Yu EY, Mostaghel EA, Cheng HH, Mulcahy H, True LD, Plymate SR, Dvinge H, Ferraldeschi R, Flohr P, Miranda S, Zafeiriou Z, Tunariu N, Mateo J, Perez-Lopez R, Demichelis F, Robinson BD, Sboner A, Schiffman M, Nanus DM, Tagawa ST, Sigaras A, Eng KW, Elemento O, Sboner A, Heath EI, Scher HI, Pienta KJ, Kantoff P, de Bono JS, Rubin MA, Nelson PS, Garraway LA, Sawyers CL, Chinnaiyan AM.

Cell. 2015 Jul 16;162(2):454. doi: 10.1016/j.cell.2015.06.053. Epub 2015 Jul 16. No abstract available.

29.

Integrative clinical genomics of advanced prostate cancer.

Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, Montgomery B, Taplin ME, Pritchard CC, Attard G, Beltran H, Abida W, Bradley RK, Vinson J, Cao X, Vats P, Kunju LP, Hussain M, Feng FY, Tomlins SA, Cooney KA, Smith DC, Brennan C, Siddiqui J, Mehra R, Chen Y, Rathkopf DE, Morris MJ, Solomon SB, Durack JC, Reuter VE, Gopalan A, Gao J, Loda M, Lis RT, Bowden M, Balk SP, Gaviola G, Sougnez C, Gupta M, Yu EY, Mostaghel EA, Cheng HH, Mulcahy H, True LD, Plymate SR, Dvinge H, Ferraldeschi R, Flohr P, Miranda S, Zafeiriou Z, Tunariu N, Mateo J, Perez-Lopez R, Demichelis F, Robinson BD, Schiffman M, Nanus DM, Tagawa ST, Sigaras A, Eng KW, Elemento O, Sboner A, Heath EI, Scher HI, Pienta KJ, Kantoff P, de Bono JS, Rubin MA, Nelson PS, Garraway LA, Sawyers CL, Chinnaiyan AM.

Cell. 2015 May 21;161(5):1215-1228. doi: 10.1016/j.cell.2015.05.001. Erratum in: Cell. 2015 Jul 16;162(2):454.

30.

SWOG S0925: A Randomized Phase II Study of Androgen Deprivation Combined With Cixutumumab Versus Androgen Deprivation Alone in Patients With New Metastatic Hormone-Sensitive Prostate Cancer.

Yu EY, Li H, Higano CS, Agarwal N, Pal SK, Alva A, Heath EI, Lam ET, Gupta S, Lilly MB, Inoue Y, Chi KN, Vogelzang NJ, Quinn DI, Cheng HH, Plymate SR, Hussain M, Tangen CM, Thompson IM Jr.

J Clin Oncol. 2015 May 10;33(14):1601-8. doi: 10.1200/JCO.2014.59.4127. Epub 2015 Apr 6.

31.

Taxane resistance in prostate cancer mediated by AR-independent GATA2 regulation of IGF2.

Plymate SR, Bhatt RS, Balk SP.

Cancer Cell. 2015 Feb 9;27(2):158-9. doi: 10.1016/j.ccell.2015.01.008.

32.

MED1 mediates androgen receptor splice variant induced gene expression in the absence of ligand.

Liu G, Sprenger C, Wu PJ, Sun S, Uo T, Haugk K, Epilepsia KS, Plymate S.

Oncotarget. 2015 Jan 1;6(1):288-304.

33.

Prostate cancer characteristics associated with response to pre-receptor targeting of the androgen axis.

Mostaghel EA, Morgan A, Zhang X, Marck BT, Xia J, Hunter-Merrill R, Gulati R, Plymate S, Vessella RL, Corey E, Higano CS, Matsumoto AM, Montgomery RB, Nelson PS.

PLoS One. 2014 Oct 30;9(10):e111545. doi: 10.1371/journal.pone.0111545. eCollection 2014.

34.

Hyaluronan in aged collagen matrix increases prostate epithelial cell proliferation.

Damodarasamy M, Vernon RB, Chan CK, Plymate SR, Wight TN, Reed MJ.

In Vitro Cell Dev Biol Anim. 2015 Jan;51(1):50-8. doi: 10.1007/s11626-014-9800-z. Epub 2014 Aug 15.

35.

The androgen receptor mediates antiapoptotic function in myometrial cells.

Li H, Li Y, Morin D, Plymate S, Lye S, Dong X.

Cell Death Dis. 2014 Jul 17;5:e1338. doi: 10.1038/cddis.2014.303.

36.

Prostate cancer xenografts engineered from 3D precision-porous poly(2-hydroxyethyl methacrylate) hydrogels as models for tumorigenesis and dormancy escape.

Long TJ, Sprenger CC, Plymate SR, Ratner BD.

Biomaterials. 2014 Sep;35(28):8164-74. doi: 10.1016/j.biomaterials.2014.04.090. Epub 2014 Jun 15.

37.

The link between androgen receptor splice variants and castration-resistant prostate cancer.

Sprenger CC, Plymate SR.

Horm Cancer. 2014 Aug;5(4):207-17. doi: 10.1007/s12672-014-0177-y. Epub 2014 May 6. Review.

38.

Decreased proliferative capacity of aged dermal fibroblasts in a three dimensional matrix is associated with reduced IGF1R expression and activation.

Bentov I, Damodarasamy M, Plymate S, Reed MJ.

Biogerontology. 2014 Aug;15(4):329-37. doi: 10.1007/s10522-014-9501-8. Epub 2014 Apr 26.

39.

Androgen receptor splice variants activating the full-length receptor in mediating resistance to androgen-directed therapy.

Cao B, Qi Y, Zhang G, Xu D, Zhan Y, Alvarez X, Guo Z, Fu X, Plymate SR, Sartor O, Zhang H, Dong Y.

Oncotarget. 2014 Mar 30;5(6):1646-56.

40.

Prostate stromal cells express the progesterone receptor to control cancer cell mobility.

Yu Y, Lee JS, Xie N, Li E, Hurtado-Coll A, Fazli L, Cox M, Plymate S, Gleave M, Dong X.

PLoS One. 2014 Mar 24;9(3):e92714. doi: 10.1371/journal.pone.0092714. eCollection 2014.

41.

Ablation of the oncogenic transcription factor ERG by deubiquitinase inhibition in prostate cancer.

Wang S, Kollipara RK, Srivastava N, Li R, Ravindranathan P, Hernandez E, Freeman E, Humphries CG, Kapur P, Lotan Y, Fazli L, Gleave ME, Plymate SR, Raj GV, Hsieh JT, Kittler R.

Proc Natl Acad Sci U S A. 2014 Mar 18;111(11):4251-6. doi: 10.1073/pnas.1322198111. Epub 2014 Mar 3.

42.

Androgen receptor splice variants determine taxane sensitivity in prostate cancer.

Thadani-Mulero M, Portella L, Sun S, Sung M, Matov A, Vessella RL, Corey E, Nanus DM, Plymate SR, Giannakakou P.

Cancer Res. 2014 Apr 15;74(8):2270-2282. doi: 10.1158/0008-5472.CAN-13-2876. Epub 2014 Feb 20.

43.

Molecular pathways: targeting resistance in the androgen receptor for therapeutic benefit.

Mostaghel EA, Plymate SR, Montgomery B.

Clin Cancer Res. 2014 Feb 15;20(4):791-8. doi: 10.1158/1078-0432.CCR-12-3601. Epub 2013 Dec 4.

44.

AR variant ARv567es induces carcinogenesis in a novel transgenic mouse model of prostate cancer.

Liu G, Sprenger C, Sun S, Epilepsia KS, Haugk K, Zhang X, Coleman I, Nelson PS, Plymate S.

Neoplasia. 2013 Sep;15(9):1009-17.

45.

Perturbation of NK cell peripheral homeostasis accelerates prostate carcinoma metastasis.

Liu G, Lu S, Wang X, Page ST, Higano CS, Plymate SR, Greenberg NM, Sun S, Li Z, Wu JD.

J Clin Invest. 2013 Oct;123(10):4410-22. doi: 10.1172/JCI69369. Epub 2013 Sep 9.

46.

Mechanisms of the androgen receptor splicing in prostate cancer cells.

Liu LL, Xie N, Sun S, Plymate S, Mostaghel E, Dong X.

Oncogene. 2014 Jun 12;33(24):3140-50. doi: 10.1038/onc.2013.284. Epub 2013 Jul 15.

47.

A study of caloric restriction versus standard diet in overweight men with newly diagnosed prostate cancer: a randomized controlled trial.

Wright JL, Plymate S, D'Oria-Cameron A, Bain C, Haugk K, Xiao L, Lin DW, Stanford JL, McTiernan A.

Prostate. 2013 Sep;73(12):1345-51. doi: 10.1002/pros.22682. Epub 2013 Jun 15.

48.

T-helper I immunity, specific for the breast cancer antigen insulin-like growth factor-I receptor (IGF-IR), is associated with increased adiposity.

Cecil DL, Park KH, Gad E, Childs JS, Higgins DM, Plymate SR, Disis ML.

Breast Cancer Res Treat. 2013 Jun;139(3):657-65. doi: 10.1007/s10549-013-2577-z. Epub 2013 Jun 8.

PMID:
23749321
49.

An androgen receptor N-terminal domain antagonist for treating prostate cancer.

Myung JK, Banuelos CA, Fernandez JG, Mawji NR, Wang J, Tien AH, Yang YC, Tavakoli I, Haile S, Watt K, McEwan IJ, Plymate S, Andersen RJ, Sadar MD.

J Clin Invest. 2013 Jul;123(7):2948-60. doi: 10.1172/JCI66398. Epub 2013 Jun 3.

50.

Constitutively-active androgen receptor variants function independently of the HSP90 chaperone but do not confer resistance to HSP90 inhibitors.

Gillis JL, Selth LA, Centenera MM, Townley SL, Sun S, Plymate SR, Tilley WD, Butler LM.

Oncotarget. 2013 May;4(5):691-704.

Supplemental Content

Loading ...
Support Center